TFS Capital’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

TFS Capital’s Portfolio JNP Stock Details JNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-16,490	Closed	-$83K	–	536
2017 Q2	$83K	Sell	16,490 -15,129	-48%	-$67.7K	0.03%	568
2017 Q1	$150K	Buy	31,619 +14,707	+87%	+$74.3K	0.05%	547
2016 Q4	$95K	Buy	16,912 +2,205	+15%	+$12.1K	0.03%	648
2016 Q3	$82K	Buy	+14,707	New	+$97.3K	0.02%	680
2016 Q1	–	Sell	-34,611	Closed	-$356K	–	1177
2015 Q4	$356K	Sell	34,611 -65,212	-65%	-$756K	0.04%	490
2015 Q3	$1.18M	Buy	+99,823	New	+$1.1M	0.11%	298

Other funds holding JNP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

MERSOM

Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return

Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TFS Capital's JNP Position: Q3 2017 in Review

TFS Capital sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2017, closing a stake of 16,490 shares — an estimated $83K sold.

TFS Capital first reported a position in JNP in Q3 2015 and held it in 6 quarters. The position peaked at $1.18M in Q3 2015. 31 funds tracked by Wall St. Rank hold JNP as of Q3 2017.

TFS Capital reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
TFS Capital sold 16,490 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2017, an estimated $83K.
TFS Capital first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2015 and held it in 6 quarters.
TFS Capital's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $1.18M in Q3 2015.
31 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.